Nintedanib Gains Promising Innovative Medicine Status in the UK
It was recently announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) designated nintedanib, an oral triple angiokinase inhibitor by Boehringer Ingelheim,
